Trade PURETECH HEALTH PLC ORD 1P - PRTC
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines targeting serious diseases that result from dysfunctions in the nervous, immune, and gastrointestinal systems. The company is developing a digital medicine platform for the treatment and assessment of cognitive dysfunction across various neurological and psychiatric indications; therapies to treat a range of acute and chronic inflammatory disorders; microbiome-derived immune modulators for maternal and paediatric health; novel approach to oral delivery of biologics, vaccines, and other drugs; platform to address androgenetic alopecia; mechanotherapeutics to treat obesity, and other chronic diseases related to the gastrointestinal pathway; muscarinic receptor agonist programme for the treatment of psychosis and cognition, including schizophrenia and Alzheimer''s; monoclonal antibody-based therapeutic to treat pancreatic cancer and other solid tumors; voice-based technology platform for monitoring and diagnosing mental and physical medical conditions, such as depression, Alzheimer''s disease, multiple sclerosis, and Parkinson''s disease; platform and products that seek to explore and leverage the health potential of music; therapies for immune-mediated and infectious diseases based on rationally-defined consortium of human microbiome-derived bacteria; and novel antibody and cell therapies for treating cancer. It is also developing a milk exosome-based technology designed to enable the oral administration of biologics, nucleic acids, and complex small molecules; and a lipid prodrug technology to enable lymphatic targeting. In addition, the company''s medical device programme is developing a non-invasive neurostimulation treatment for psychiatric disorders, including depression and bipolar disorder. PureTech Health plc was incorporated in 2015 and is headquartered in Boston, Massachusetts. 
NVIDIA stock forecast: Q3 earnings, CEO transitionUS semiconductor giant NVIDIA (NVDA) reported third-quarter fiscal 2027 revenue of $115.8bn on 17 November 2026, up 103% year on year. Explore third-party price targets and technical analysis. Past performance isn't a reliable indicator of future results.
20 hours ago

AMC Entertainment stock forecast: record revenue, summer box officeAMC Entertainment is a US cinema operator whose latest results showed record quarterly revenue of about $1.6bn and a surprise adjusted profit, supported by a stronger summer box office. Explore third-party AMC price targets and technical analysis.
09:15, 12 November 2026